Myeloproliferative neoplasms trials in United Kingdom

In United Kingdom 21 Also abroad 210

21 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Asciminib Roll-over Study
Where
London, Oxford
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 3Taking people
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Where
Birmingham, Leicester, Lincoln, London, Sunderland
Age
18 years and over
People
324 worldwide
Run by
Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00
Phase 3Taking people
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Where
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
Age
18 years and over
People
426 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00
Phase 1Taking people
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Where
London, Oxford
Age
18 years and over
People
300 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00
Phase 1Taking people
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Where
London, Nottingham, Oxford
Age
18 years and over
People
218 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00
Phase 3Taking people
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Where
Exeter, London, Newcastle upon Tyne, Newport, Nottingham, Oxford, Windsor
Age
18 years and over
People
250 worldwide
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00
Phase 3Taking people
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Where
Aberdeen, Bath, Belfast, Birmingham, Blackpool, Bodelwyddan, Bournemouth, Bristol, Cambridge, Canterbury, Cardiff, Chichester, Colchester, Cottingham, Coventry, Dudley, Edinburgh, Exeter, Gloucester, Halifax, Huddersfield, Inverness, Ipswich, Kettering, Leeds, Leicester, Livingston, London, Manchester, Metropolitan Borough of Wirral, Middlesbrough, Newcastle upon Tyne, Newport, Northampton, North Shields, Norwich, Nottingham, Nuneaton, Oxford, Plymouth, Reading, Runcorn, Sheffield, Slough, Southampton, Stoke-on-Trent, Sunderland, Sutton Coldfield, Truro, Warwick, Wolverhampton, Worthing, York
Age
18 years and over
People
586
Run by
University of Birmingham
See details and how to joinNCT04116502
Phase 1Taking people
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Where
London, Oxford
Age
18 years and over
People
256 worldwide
Run by
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
See details and how to joinNCT06343805 · EU 2025-522033-64-00
Phase 1/2Taking people
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Where
Lincoln, London, Oxford
Age
18 years and over
People
240 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Leeds, London
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Edinburgh, Greater Manchester
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
No phaseTaking people
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Where
London
Age
18 years to 100 years
People
678 worldwide
Run by
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT07203768
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Aberdeen, Leeds, London, Oxford, Sutton in Ashfield
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Phase 1/2Taking people
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Where
Belfast, Boston, London
Age
18 years and over
People
26 worldwide
Run by
iOnctura
See details and how to joinNCT06887803
Phase 2Taking people
A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
Where
Cardiff, London, Oxford, Sheffield, Southampton
Age
18 years and over
People
50 worldwide
Run by
Step Pharma, SAS
See details and how to joinNCT06786234
Phase 2Taking people
Methods of T Cell Depletion Trial (MoTD)
Where
Birmingham, Bristol, Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Plymouth, Sheffield, Sutton
Age
16 years to 70 years
People
400
Run by
University of Birmingham
See details and how to joinNCT04888741
Phase 3Taking people
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Where
Boston, London
Age
18 years and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06351631 · EU 2023-506996-89-00
Phase 3Taking people
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Where
Belfast, Boston, London, Milton Keynes, Oxford, Southampton
Age
18 years and over
People
220 worldwide
Run by
Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00
Phase 2Taking people
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Where
London
Age
18 years and over
People
58 worldwide
Run by
Karyopharm Therapeutics Inc
See details and how to joinNCT05980806
Phase 2Taking people
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Where
Boston, Leeds, London
Age
18 years and over
People
135 worldwide
Run by
Takeda
See details and how to joinNCT05037760 · EU 2023-507468-38-00
Phase 3Taking people
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Where
Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester, Liverpool, London, Oxford, Windsor
Age
18 years and over
People
600 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT06479135